Literature DB >> 29801989

Ten-year survival in glioblastoma. A systematic review.

Tomasz Tykocki1, Mohamed Eltayeb2.   

Abstract

Glioblastoma (GBM) is among the most deadly neoplasms associated with one of the worst 5-year overall survival (OS) rates among all human cancers. The aim of this systematic review is to present all cases with OS of a decade or more and to perform a descriptive analysis of the group. This systematic review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A comprehensive search for relevant articles was performed on PubMed, Embase and Google Scholar for a period until June 10, 2016, using the following search words: glioblastoma multiforme, glioblastoma, GBM, long-term survival/survivors. Reports containing cases with the long-term survival of 10 years or longer were included in the review. The search produced 36 studies with 162 cases published in the years 1950-2014. The rate of long survivors in the cohort studied was established 0.76%. Mean age at diagnosis, OS and PFS were 31.1 ± 11.1, 15.9 ± 6.3, 11.9 ± 5.6 years respectively. Total and subtotal resections were found in 82 and 58 patients respectively. Nine cases received a biopsy alone. No statistical differences were found in a comparison of PFS, OS and age between total and subtotal resection groups. A regression analysis showed a significant correlation between PFS and OS, with an inverse relationship stated between age at diagnosis and OS. The 10-year survival rate in the cohort studied with GBM was estimated 0.71%. OS was positively correlated with the length of PFS and inversely related with age at diagnosis.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  10 years; Glioblastoma; Long-term survival; Progression-free survival

Mesh:

Year:  2018        PMID: 29801989     DOI: 10.1016/j.jocn.2018.05.002

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  70 in total

Review 1.  Late effects of cancer treatment: consequences for long-term brain cancer survivors.

Authors:  Montse Alemany; Roser Velasco; Marta Simó; Jordi Bruna
Journal:  Neurooncol Pract       Date:  2020-07-16

2.  Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

Authors:  So Young Ji; Jongjin Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong Hwy Kim; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Yongdai Kim; Chul-Kee Park
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

3.  Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.

Authors:  Dingyuan Luo; Magdalena Fraga-Lauhirat; Jonathan Millings; Cristella Ho; Emily M Villarreal; Teresa C Fletchinger; James V Bonfiglio; Leyda Mata; Matthew D Nemesure; Lauren E Bartels; Ruixue Wang; Basil Rigas; Gerardo G Mackenzie
Journal:  Carcinogenesis       Date:  2019-12-31       Impact factor: 4.944

4.  Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.

Authors:  Riccardo Muglia; Matteo Simonelli; Federico Pessina; Emanuela Morenghi; Pierina Navarria; Pasquale Persico; Elena Lorenzi; Angelo Dipasquale; Marco Grimaldi; Marta Scorsetti; Armando Santoro; Letterio S Politi
Journal:  Eur Radiol       Date:  2020-11-17       Impact factor: 5.315

5.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

6.  Long-term Survival in a Patient with Butterfly Glioblastoma: A Case Report.

Authors:  Megan Finneran; Dario A Marotta; Dana Altenburger; Emilio Nardone
Journal:  Cureus       Date:  2020-02-07

7.  Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt.

Authors:  Ahmed El-Sehemy; Hayden Selvadurai; Arturo Ortin-Martinez; Neno Pokrajac; Yasin Mamatjan; Nobuhiko Tachibana; Katherine Rowland; Lilian Lee; Nicole Park; Kenneth Aldape; Peter Dirks; Valerie A Wallace
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 8.  Why Great Mitotic Inhibitors Make Poor Cancer Drugs.

Authors:  Victoria C Yan; Hannah E Butterfield; Anton H Poral; Matthew J Yan; Kristine L Yang; Cong-Dat Pham; Florian L Muller
Journal:  Trends Cancer       Date:  2020-06-11

Review 9.  Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease.

Authors:  Jamal M Bryant; Raymond D Blind
Journal:  J Lipid Res       Date:  2018-09-10       Impact factor: 5.922

10.  Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.

Authors:  Tyler Shugg; Nimita Dave; Enoch Amarh; Abdullah A Assiri; Karen E Pollok; Brian R Overholser
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-10-27       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.